Indian Journal of PharmacologyThe antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice
The takeaway
One of the newly developed xanthone–piperazine compounds, HBK-5, exhibited both antidepressant and anxiety-reducing effects in mice, without impacting memory or motor skills-making it a promising candidate for future drug development.
The science
Of the four xanthone-based compounds tested, only HBK-5 reduced signs of depression-like behavior (immobility) in both the forced swim and tail suspension tests, and it also showed anxiety-reducing effects in a four-plate test. These behavioral benefits occurred at doses that did not impair learning, memory, or muscle coordination. In contrast, other derivatives either lacked these effects or caused increased movement, indicating stimulation rather than therapeutic benefit.
Why it matters
HBK-5’s combined mood-boosting and anxiety-reducing effects, along with its clean safety profile in animal tests, make it a promising candidate for further research in treating affective disorders.
Original article
Our other publications
The initiative focuses on promotion techniques that can revolutionize traditional research approaches pharmaceuticals.
